|
Biotech News Company news Regular news within the Australian biotech industry. |
- BresaGen awarded BioInnovations SA grant
- Genesis buys into fertility testing
- Healthscope completes Nova acquisition
- Life Therapeutics bolsters US presence
- Progen cancer program backed by $3.4 million grant
BresaGen awarded BioInnovations SA grant
July 19 – BresaGen has been awarded a AU$200,000 BioInnovations SA Commercial Infrastructure Grant toward the purchase of an aseptic filling line to enable medium scale sterile filling for use with production of bacterially sourced peptides. BresaGen anticipates commissioning the equipment in the first quarter of 2006.
[Source: Company Announcement]
Genesis buys into fertility testing
July 18 – Genesis Biomedical has signed an agreement for the purchase of the private New Zealand based biotechnology company Manuatu Biotech Investments Limited. The agreements provides Genesis with access to fertility testing markets in which MBIL holds developmental proprietary technology in the form of test strips that measure hormone metabolites for both human females and other mammals. Genesis is currently considering appropriate capital raising in light of the recent acquisition and proposed four phase developmental process.
[Source: Company Announcement]
Healthscope completes Nova acquisition
July 25 - Healthscope has completed the compulsory acquisition of outstanding shares in Nova Health Limited following an unconditional off market bid by Healthscope on 30 May 2005. The bid was supported by the placement of approximately AU$77.5 million in ordinary shares to institutional shareholders.
[Source: Company Announcement]
Life Therapeutics bolsters US presence
July 26 – Life Therapeutics will relocate two of its three business divisions from Sydney to Altanta, US. The corporate office and both the diagnostics and bioprocess production divisions will be transferred to the US by the end of Q1 2006. Life Therapeutics cited recent US acquisitions and centralisation of the company's major activities to gain better access to US Food and Drug Administration resources as major impetus for the move. The Australian office will remain company headquarters.
[Source: Company Announcement]
Progen cancer program backed by $3.4 million grant
July 25 – Progen Industries has announced that it intends to accept a AU$3.39 million AusIndustry Commercial Ready grant to support its maturing cancer drug pipelines over the next three years. The funding will provide 50 per cent of the required budget to develop early stage compounds for entry into clinical trials. The new grant follows on from previous AusIndustry funding that aided in generating new angiogenesis mediating compounds and IP expanding Progen's portfolio to include 15 patent families and 24 issued patents.
[Source: Company Announcement]
